prikaz prve stranice dokumenta Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
Kidney & blood pressure research, 34 (2011), 1; 53-57. https://doi.org/10.1159/000322922
Bašić-Jukić, Nikolina; Gulin, Marijana; Slaviček, Jasna; Čorić Martinović, Valentina; Iskra, Bosiljka; Rački, Sanjin; Šain, Milenka; Ostojić, Rajko; Hrstić, Irena; Ljutić, Dragan; Vucelić, Boris; Kes, Petar

Citirajte ovaj rad

Bašić Jukić, N., Gulin, M., Slaviček, J., Čorić Martinović, V., Iskra, B., Rački, S. ... Kes, P. (2011). Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia. Kidney & blood pressure research, 34. (1), 53-57. doi: 10.1159/000322922

Bašić Jukić, Nikolina, et al. "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia." Kidney & blood pressure research, vol. 34, br. 1, 2011, str. 53-57. https://doi.org/10.1159/000322922

Bašić Jukić, Nikolina, Marijana Gulin, Jasna Slaviček, Valentina Čorić Martinović, Bosiljka Iskra, Sanjin Rački, Milenka Šain, et al. "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia." Kidney & blood pressure research 34, br. 1 (2011): 53-57. https://doi.org/10.1159/000322922

Bašić Jukić, N., et al. (2011) 'Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia', Kidney & blood pressure research, 34(1), str. 53-57. doi: 10.1159/000322922

Bašić Jukić N, Gulin M, Slaviček J, Čorić Martinović V, Iskra B, Rački S, i sur.. Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia. Kidney & blood pressure research [Internet]. 2011. [pristupljeno 19.11.2024.];34(1):53-57. doi: 10.1159/000322922

N. Bašić Jukić, et al., "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia", Kidney & blood pressure research, vol. 34, br. 1, str. 53-57, 2011. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:707696. [Citirano: 19.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:707696
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
AutorNikolina Bašić-Jukić
AutorMarijana Gulin
AutorJasna Slaviček
AutorValentina Čorić Martinović
AutorBosiljka Iskra
AutorSanjin Rački
AutorMilenka Šain
AutorRajko Ostojić
AutorIrena Hrstić
AutorDragan Ljutić
AutorBoris Vucelić
AutorPetar Kes
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Hepatitis C virus (HCV) infection is a frequent complication among long-term dialysis patients. The aim of the present study was to evaluate the efficacy and side effects of pegylated interferon-α(2a) (PEG-IFN-α(2a)) treatment in hemodialysis patients. We retrospectively reviewed charts of 16 HCV-RNA-positive hemodialysis patients. There were 11 male and 5 female patients treated with dialysis for 6-28 years. Twelve patients had HCV genotype 1b, 2 patients had 3a, and 1 patient had genotype 2a. Although only 10 out of 16 patients completed 48 weeks of treatment, early virological response and end-of-treatment virological response were achieved in 9 and 13 patients, respectively. Sustained virological response was recorded in 9 patients. The most common side effect was anemia. A flu-like syndrome was documented in 6, myalgia in 4, and arthralgia in 5 patients. Rectorrhagia, endocarditis and severe cough were recorded in 1 patient each. Nine patients received a renal transplant, and all 6 responders remained HCV-RNA-negative. PEG-IFN-α(2a) has limited efficacy in dialysis patients. A significant proportion of patients discontinued treatment because of side effects. Additional studies with long-term follow-up are needed to determine the optimal treatment of HCV infection in the dialysis population.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaKidney & blood pressure research
Brojčani podacivol. 34, br. 1, str. 53-57
p-ISSN1420-4096
DOIhttps://doi.org/10.1159/000322922
URN:NBNurn:nbn:hr:184:707696
Datum objave publikacije2011
ProjektŠifra: 062-0000000-3550
Naziv (hrvatski): Molekularni mehanizmi infekcije virusom hepatitisa C
Naziv (engleski): Molecular mechanisms of infection with hepatitis C virus
Voditelj: Blaženka Grahovac
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZP
ProjektŠifra: 108-0000000-3499
Naziv (hrvatski): Prevencija, rano prepoznavanje i liječenje kroničnog zatajenja bubrega
Naziv (engleski): Prevention, early detection and tretament of chronic renal failure
Voditelj: Petar Kes
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZP
ProjektŠifra: 108-1080134-0122
Naziv (hrvatski): Čimbenici rizika za razvoj ateroskleroze nakon transplantacije bubrega
Naziv (engleski): Risk factors for development of atherosclerosis after renal transplantation
Voditelj: Nikolina Bašić-Jukić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZP
URL dokumentahttp://bib.irb.hr/544630
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-04-20 09:48:37